Flush with $126M raise, Tessa Therapeutics woos new CEO from Takeda

After some repositioning — and a $126 million financing round to take it down that direction — Singapore’s Tessa Therapeutics has found a new captain to steer the ship.

Thomas Willemsen is jumping from Takeda, where he was most recently SVP, Asia-Pacific, to spearhead Tessa’s drive to develop new CAR-T therapies, including both autologous and off-the-shelf ones.